Bladder cancer treatment remains a challenge to every oncologist. We report the case of a 57-year-old man with BCG-refractory bladder cancer, who had a complete response to the intravesical Gemcitabine to shine the light on the role of Gemcitabine as a bladder sparing treatment in BCG-failure patients.